





Figure S1. Random-effects fit of model [2] (main text) to the raltegravir monotherapy data alone. The horizontal dashed line indicates the LOQ=400 copies/ml for the main assay used in the study. Data points below the dashed line were tested with a more sensitive assay with LOQ=50 copies/ml.







Viral load (log10)





Time (days)


Table S1. ESTIMATED PARAMETERS


	PID	V0	τ	$\delta 1$	$\delta 2$	ω	η	k
Combination Tx	C1	4.79	0.47	0.08	0.72	0.938	0.95	2.6
	C2	4.43	0.47	0.14	0.89	0.942	0.95	2.6
	C5	4.59	0.47	0.14	1.31	0.945	0.95	2.6
	C6	5.94	0.47	0.25	1.11	0.953	0.95	2.6
	C13	4.64	0.47	0.25	0.67	0.932	0.95	2.6
	C15	4.94	0.47	0.08	0.89	0.938	0.95	2.6
	C16	4.42	0.47	0.13	0.81	0.938	0.95	2.6
	C26	4.47	0.47	0.09	0.90	0.937	0.95	2.6
	C27	4.42	0.47	0.12	0.97	0.944	0.95	2.6
	C28	4.79	0.47	0.28	0.93	0.940	0.95	2.6
	C32	4.95	0.47	0.18	0.78	0.940	0.95	2.6
Monotherapy	M1	3.89	0.47	0.19	1.14	0.997	0	2.6
	M2	4.32	0.47	0.52	0.79	0.997	0	2.6
	M4	3.79	0.47	0.20	0.86	0.997	0	2.6
	M6	4.22	0.47	0.18	1.03	0.997	0	2.6
	M7	4.68	0.47	0.10	0.76	0.996	0	2.6
	M8	4.30	0.47	0.12	0.67	0.996	0	2.6
	M10	4.27	0.47	0.53	1.22	0.997	0	2.6
	M11	3.61	0.47	0.14	0.92	0.997	0	2.6
	M12	3.83	0.47	0.23	1.06	0.997	0	2.6
	M13	4.97	0.47	0.14	0.77	0.997	0	2.6
	M15	4.04	0.47	0.13	1.05	0.997	0	2.6
	M16	4.72	0.47	0.46	1.17	0.997	0	2.6
	M17	4.49	0.47	0.05	1.47	0.997	0	2.6
	M18	3.89	0.47	0.19	1.09	0.997	0	2.6
	M84	5.39	0.47	0.11	0.80	0.996	0	2.6
	M85	5.12	0.47	0.28	1.03	0.997	0	2.6
	M86	5.10	0.47	0.24	1.05	0.997	0	2.6
	M88	5.10	0.47	0.22	0.71	0.997	0	2.6
	M89	5.06	0.47	0.06	0.62	0.994	0	2.6
	M90	4.86	0.47	0.07	0.57	0.995	0	2.6
	M91	5.05	0.47	0.27	0.66	0.997	0	2.6
	M92	5.03	0.47	0.08	0.69	0.995	0	2.6
	M93	5.22	0.47	0.10	1.16	0.997	0	2.6
	M94	5.04	0.47	1.02	1.25	0.997	0	2.6
	M96	4.93	0.47	0.19	0.72	0.996	0	2.6
	M97	4.94	0.47	0.07	0.98	0.996	0	2.6
	M99	5.68	0.47	0.08	0.95	0.996	0	2.6
	M100	5.03	0.47	0.17	0.98	0.997	0	2.6

Figure S2. Random-effects fit of model [2] (main text) to the monotherapy and combination therapy data together. Patients labeled C followed by a number were given combination therapy. The horizontal dashed line indicates the LOQ=400 copies/ml for the main assay used in the raltegravir monotherapy study. Data points below the dashed line were tested with a more sensitive assay with LOQ=50 copies/ml.










Viral load (log10)



Time (days)